BioFilm Pharma brings its innovative approach by addressing the chronic disease and long-term treatment of “diabete foot ulcers” (15 million new patients each year), which represent a heavy cost for health care system in high-income countries (4 billions €). BioFilm Pharma holds the unique proprietary technology to develop first-in-class products able to prevent and cure the metastatic bacterial infections named biofilms considered as the new paradigm in the antibiotherapy. We have already 5 compounds in our pipeline and are 3 years up to proof-of-concept in patients for potential blockbusters. We have already 2,4 M€ secured by a syndicate of historic investors or grants and we are looking for 20 M€ funds to engage CMC, preclinical and clinical studies.
BioFilm Pharma brings its innovative approach by addressing the chronic disease and long-term treatment of “diabete foot ulcers” (15 million new patients each year), which represent a heavy cost for health care system in high-income countries (4 billions €). BioFilm Pharma holds the unique proprietary technology to develop first-in-class products able to prevent and cure the metastatic bacterial infections named biofilms considered as the new paradigm in the antibiotherapy. We have already 5 compounds in our pipeline and are 3 years up to proof-of-concept in patients for potential blockbusters. We have already 2,4 M€ secured by a syndicate of historic investors or grants and we are looking for 20 M€ funds to engage CMC, preclinical and clinical studies.
Company Information
- Industry
- Company Type
- Privately Held
- Founded
- 2017
- Employee Range
- 1-10
- Revenue Range
- Not available
Location
- Address
- 317, Avenue Jean Jaurès Auvergne-Rhône-Alpes Lyon
- City
- Sherwood Park
- Region
- Alberta
- Postal Code
- 69007
- Country
- Canada
